ALFONSO CARVAJAL GARCIA PANDO-rekin lankidetzan egindako argitalpenak (11)

2021

  1. Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case–control study

    Scientific Reports, Vol. 11, Núm. 1

2015

  1. Emergency contraceptive pill safety profile. Comparison of the results of a follow-up study to those coming from spontaneous reporting

    Pharmacoepidemiology and Drug Safety, Vol. 24, Núm. 1, pp. 93-97

2014

  1. A European community pharmacy-based survey to investigate patterns of prescription fraud through identification of falsified prescriptions

    European Addiction Research, Vol. 20, Núm. 4, pp. 174-182

  2. Knowledge upon the emergency contraceptive pill in Spain

    Atencion Farmaceutica, Vol. 16, Núm. 3, pp. 224-228

2013

  1. Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study

    European Journal of Clinical Pharmacology, Vol. 69, Núm. 3, pp. 559-564

2012

  1. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): Changes in the consumption pattern following the introduction of extended release methylphenidate

    Pharmacoepidemiology and Drug Safety, Vol. 21, Núm. 4, pp. 435-441

2011

  1. Adverse events associated with pandemic influenza vaccines: Comparison of the results of a follow-up study with those coming from spontaneous reporting

    Vaccine, Vol. 29, Núm. 3, pp. 519-522

2010

  1. Response to rupatadine and heart rhythm disturbances

    Clinical Pharmacology and Therapeutics

2009

  1. Heart rhythm disturbances associated with rupatadine: A case series from the Spanish and Portuguese pharmacovigilance systems

    Clinical Pharmacology and Therapeutics, Vol. 85, Núm. 5, pp. 481-484

2007

  1. Gynaecomastia associated with proton pump inhibitors: A case series from the Spanish pharmacovigilance system

    Drug Safety, Vol. 30, Núm. 6, pp. 527-531

2006

  1. HMG CoA reductase inhibitors and impotence: Two case series from the Spanish and French drug monitoring systems

    Drug Safety, Vol. 29, Núm. 2, pp. 143-149